A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
Clinical trial NCT05203445 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05203445
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-31
- Primary completion
- 2025-05-29
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.